Donoghoe Nicholas 4

What Happened

• Nicholas Donoghoe, Executive Vice President and Chief Business & Strategy Officer of AbbVie (ABBV), was granted multiple performance-based equity awards reported on Feb 18, 2026. The filing shows acquisition of 13,031; 4,632; 5,172; and 6,222 shares (total 29,057) at $0, and a derivative award (stock option) covering 20,312 shares at $0. The performance restrictions were certified as met by the Compensation Committee; the shares will be issued to Donoghoe on February 28, 2026. The option is a standard employee stock option (see vesting schedule below).

Key Details

• Transaction date reported: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely).
• Price reported: $0.00 for all items (typical for awards/grants).
• Award breakdown: 13,031; 4,632; 5,172; 6,222 common shares (performance-vested awards) and a stock option covering 20,312 shares (derivative).
• Option vesting: exercisable in annual increments of 6,771 on 2/18/2027, 6,771 on 2/18/2028, and 6,770 on 2/18/2029 (total 20,312) — grant per AbbVie’s 2013 Incentive Stock Program.
• Footnotes: F1–F4 — performance-based restricted stock/share awards granted in 2023–2025 with vesting tied to EPS, relative TSR, or return on equity; restrictions were released upon certification. F5 — employee stock option granted under plan.
• Shares owned after transaction: not provided in the excerpt of this filing.
• No 10b5-1 plan, tax-withholding sale, or late-filing indicator noted in the provided data.

Context

• These entries are awards/grants (transaction code A) rather than open-market purchases or sales; they reflect compensation and performance-based pay rather than a direct insider buy/sell signal.
• The $0 acquisition amounts indicate issuance of awards (not a cash purchase). The option grant is not an exercise; it will vest over the next three years per the schedule above.